Targeting microglia for the treatment of Alzheimer's Disease

GLIA

Volumn 64, Issue 10, 2016, Pages 1710-1732

  Wes, Paul D ^a   Sayed, Faten A ^b   Bard, Frédérique ^c   Gan, Li ^b  

^a LUNDBECK RESEARCH USA   (United States)

^b GLADSTONE INSTITUTES   (United States)

^c Janssen Prevention Center Janssen Pharmaceutical Companies of Johnson and Johnson   (United States)

Author keywords

Alzheimer's disease; amyloid; immunotherapy; microglia; tau

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; FC RECEPTOR; PROGRANULIN; TAU PROTEIN;

ALZHEIMER DISEASE; APOE GENE; CD33 GENE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC ASSOCIATION STUDY; GENETIC POLYMORPHISM; GENETIC RISK; GRN GENE; HUMAN; IL1RAP GENE; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; MICROGLIA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TREM2 GENE;

EID: 84985023554     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22988     Document Type: Review

References (242)

1. Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, Lohmann S, Piorkowska K, Gafner V, Atwal JK, Maloney J, Chen M, Gogineni A, Weimer RM, Mortensen DL, Friesenhahn M, Ho C, Paul R, Pfeifer A, Muhs A, Watts RJ. 2012. An effector-reduced anti-β-amyloid (Aβ) antibody with unique Aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci 32:9677–9689.
2. Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FMV. 2007. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci 10:1538–1543.
3. Andreasen N, Simeoni M, Ostlund H, Lisjo PI, Fladby T, Loercher AE, Byrne GJ, Murray F, Scott-Stevens PT, Wallin A. 2015. First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: A randomized, placebo-controlled study. PloS ONE 10:e0098153.
4. Asai H, Ikezu S, Tsunoda S, Medalla M, Luebke J, Haydar T, Wolozin B, Butovsky O, Kugler S, Ikezu T. 2015. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci 18:1584–1593.
5. Askmyr M, Agerstam H, Hansen N, Gordon S, Arvanitakis A, Rissler M, Juliusson G, Richter J, Jaras M, Fioretos T. 2013. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood 121:3709–3713.
6. Atagi Y, Liu CC, Painter MM, Chen XF, Verbeeck C, Zheng H, Li X, Rademakers R, Kang SS, Xu H, Younkin S, Das P, Fryer JD, Bu G. 2015. Apolipoprotein E is a ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). J Biol Chem 290:26043–26050.
7. Atwal JK, Chen Y, Chiu C, Mortensen DL, Meilandt WJ, Liu Y, Heise CE, Hoyte K, Luk W, Lu Y, Peng K, Wu P, Rouge L, Zhang Y, Lazarus RA, Scearce-Levie K, Wang W, Wu Y, Tessier-Lavigne M, Watts RJ. 2011. A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo. Sci Transl Med 3:84ra43–84ra43.
8. Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, Hyman BT. 2002. Non-Fc-mediated mechanisms are involved in clearance of amyloid-b in vivo by immunotherapy. J Neurosci 22:7873–7878.
9. Bailey CC, DeVaux LB, Farzan M. 2015. The triggering receptor expressed on myeloid cells 2 binds apolipoprotein E. J Biol Chem 290:26033–26042.
10. Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S, Cannon A, Dwosh E, Neary D, Melquist S, Richardson A, Dickson D, Berger Z, Eriksen J, Robinson T, Zehr C, Dickey CA, Crook R, McGowan E, Mann D, Boeve B, Feldman H, Hutton M. 2006. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442:916–919.
11. Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, Seubert P, Yednock T. 2003. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA 100:2023–2028.
12. Bard F, Cannon C, Barbour R, Burke R-L, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K. 2000a. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6:916–919.
13. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T. 2000b. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6:916–919.
14. Bardehle S, Rafalski VA, Akassoglou K. 2015. Breaking boundaries—coagulation and fibrinolysis at the neurovascular interface. Front Cell Neurosci 9:354.
15. Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling RP, Cripe L, Fernandez HF, Greenberg PL, Tallman MS, Steidl C, Mitsiades CS, Verma A, Steidl U. 2012. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood 120:1290–1298.
16. Baruch K, Deczkowska A, Rosenzweig N, Tsitsou-Kampeli A, Sharif AM, Matcovitch-Natan O, Kertser A, David E, Amit I, Schwartz M. 2016. PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease. Nat Med 22:135–137.
17. Beach TG, Walker R, McGeer EG. 1989. Patterns of gliosis in Alzheimer's disease and aging cerebrum. Glia 2:420–436.
18. Béchade C, Cantaut-Belarif Y, Bessis A. 2013. Microglial control of neuronal activity. Front Cell Neurosci 7:32.
19. Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, Holtzman DM, Betsholtz C, Armulik A, Sallstrom J, Berk BC, Zlokovic BV. 2012. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485:512–516.
20. Benitez BA, Jin SC, Guerreiro R, Graham R, Lord J, Harold D, Sims R, Lambert JC, Gibbs JR, Bras J, Sassi C, Harari O, Bertelsen S, Lupton MK, Powell J, Bellenguez C, Brown K, Medway C, Haddick PC, van der Brug MP, Bhangale T, Ortmann W, Behrens T, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD, Haines JL, Turton J, Braae A, Barber I, Fagan AM, Holtzman DM, Morris JC, Williams J, Kauwe JS, Amouyel P, Morgan K, Singleton A, Hardy J, Goate AM, Cruchaga C. 2014. Missense variant in TREML2 protects against Alzheimer's disease. Neurobiol Aging 35:1510 e1519–1526.
21. Bertram L, Lill CM, Tanzi RE. 2010. The genetics of Alzheimer disease: back to the future. Neuron 68:270–281.
22. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. 2007. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39:17–23.
23. Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM, Lamb BT. 2010. Regulation of tau pathology by the microglial fractalkine receptor. Neuron 68:19–31.
24. Bianchin MM, Capella HM, Chaves DL, Steindel M, Grisard EC, Ganev GG, da Silva Junior JP, Neto Evaldo S, Poffo MA, Walz R, Carlotti Junior CG, Sakamoto AC. 2004. Nasu-Hakola disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy–PLOSL): A dementia associated with bone cystic lesions. From clinical to genetic and molecular aspects. Cell Mol Neurobiol 24:1–24.
25. Boche D, Perry VH, Nicoll JA. 2013. Review: Activation patterns of microglia and their identification in the human brain. Neuropathol Appl Neurobiol 39:3–18.
26. Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, Messer J, Oroszlan K, Rauchenberger R, Richter WF. 2011. Gantenerumab: A novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J Alzheimers Dis 28:49–69.
27. Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, Messer J, Oroszlan K, Rauchenberger R, Richter WF, Rothe C, Urban M, Bardroff M, Winter M, Nordstedt C, Loetscher H. 2012. Gantenerumab: A novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis 28:49–69.
28. Bradshaw EM, Chibnik LB, Keenan BT, Ottoboni L, Raj T, Tang A, Rosenkrantz LL, Imboywa S, Lee M, Von Korff A, Morris MC, Evans DA, Johnson K, Sperling RA, Schneider JA, Bennett DA, De Jager PL. 2013. CD33 Alzheimer's disease locus: Altered monocyte function and amyloid biology. Nat Neurosci 16:848–850.
29. Britschgi M, Wyss-Coray T. 2007. Immune cells may fend off Alzheimer disease. Nat Med 13:408–409.
30. Brody DL, Holtzman DM. 2008. Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 31:175–193.
31. Brouwers N, Nuytemans K, van der Zee J, Gijselinck I, Engelborghs S, Theuns J, Kumar-Singh S, Pickut BA, Pals P, Dermaut B, Bogaerts V, De Pooter T, Serneels S, Van den Broeck M, Cuijt I, Mattheijssens M, Peeters K, Sciot R, Martin JJ, Cras P, Santens P, Vandenberghe R, De Deyn PP, Cruts M, Van Broeckhoven C, Sleegers K. 2007. Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Arch Neurol 64:1436–1446.
32. Brouwers N, Sleegers K, Engelborghs S, Maurer-Stroh S, Gijselinck I, van der Zee J, Pickut BA, Van den Broeck M, Mattheijssens M, Peeters K, Schymkowitz J, Rousseau F, Martin JJ, Cruts M, De Deyn PP, Van Broeckhoven C. 2008. Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease. Neurology 71:656–664.
33. Bruhns P. 2012. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119:5640–5649.
34. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, Daeron M. 2009. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113:3716–3725.
35. Cantoni C, Bollman B, Licastro D, Xie M, Mikesell R, Schmidt R, Yuede CM, Galimberti D, Olivecrona G, Klein RS, Cross AH, Otero K, Piccio L. 2015. TREM2 regulates microglial cell activation in response to demyelination in vivo. Acta Neuropathol 129:429–447.
36. Carrasquillo MM, Belbin O, Hunter TA, Ma L, Bisceglio GD, Zou F, Crook JE, Pankratz VS, Dickson DW, Graff-Radford NR, Petersen RC, Morgan K, Younkin SG. 2010. Replication of CLU, CR1, and PICALM associations with Alzheimer disease. Arch Neurol 67:961–964.
37. Carty NC, Wilcock DM, Rosenthal A, Grimm J, Pons J, Ronan V, Gottschall PE, Gordon MN, Morgan D. 2006. Intracranial administration of deglycosylated C-terminal-specific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. J Neuroinflamm 3:2094–2093.
38. Cataldo AM, Barnett JL, Berman SA, Li J, Quarless S, Bursztajn S, Lippa C, Nixon RA. 1995. Gene expression and cellular content of cathepsin D in Alzheimer's disease brain: Evidence for early up-regulation of the endosomal-lysosomal system. Neuron 14:671–680.
39. Chan G, White CC, Winn PA, Cimpean M, Replogle JM, Glick LR, Cuerdon NE, Ryan KJ, Johnson KA, Schneider JA, Bennett DA, Chibnik LB, Sperling RA, Bradshaw EM, De Jager PL. 2015. CD33 modulates TREM2: Convergence of Alzheimer loci. Nat Neurosci 18:1556–1558.
40. Chen H-K, Liu Z, Meyer-Franke A, Brodbeck J, Miranda RD, McGuire JG, Pleiss MA, Ji Z-S, Balestra ME, Walker DW, Xu Q, Jeong D-E, Budamagunta MS, Voss JC, Freedman SB, Weisgraber KH, Huang Y, Mahley RW. 2012. Small molecule structure correctors abolish detrimental effects of Apolipoprotein E4 in cultured neurons. J Biol Chem 287:5253–5266.
41. Chiao P, Miao X, O'Gorman J, Sevigny J, Williams L. 2015. Randomized, double-blind, phase 1B study of BIIB037, an anti-amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer's disease. In: The 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders, Nice, France, March 18–22, 2015.
42. Cho S-H, Chen JA, Sayed F, Ward ME, Gao F, Nguyen TA, Krabbe G, Sohn PD, Lo I, Minami S. 2015. SIRT1 deficiency in microglia contributes to cognitive decline in aging and neurodegeneration via epigenetic regulation of IL-1β. J Neurosci 35:807–818.
43. Cho S-H, Sun B, Zhou Y, Kauppinen TM, Halabisky B, Wes P, Ransohoff RM, Gan L. 2011. CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. J Biol Chem 286:32713–32722.
44. Chung W-S, Welsh CA, Barres BA, Stevens B. 2015. Do glia drive synaptic and cognitive impairment in disease? Nat Neurosci 18:1539–1545.
45. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, Jucker M, Goedert M, Tolnay M. 2009. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11:909–913.
46. Colonna M. 2003. TREMs in the immune system and beyond. Nat Rev Immunol 3:445–453.
47. Congdon EE, Krishnaswamy S, Sigurdsson EM. 2014. Harnessing the immune system for treatment and detection of tau pathology. J Alzheimers Dis 40:S113–S121.
48. Cortini F, Fenoglio C, Guidi I, Venturelli E, Pomati S, Marcone A, Scalabrini D, Villa C, Clerici F, Dalla Valle E, Mariani C, Cappa S, Bresolin N, Scarpini E, Galimberti D. 2008. Novel exon 1 progranulin gene variant in Alzheimer's disease. Eur J Neurol 15:1111–1117.
49. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE. 2012. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335:1503–1506.
50. Crocker P, Hartnell A, Munday J, Nath D. 1997. The potential role of sialoadhesin as a macrophage recognition molecule in health and disease. Glycoconj J 14:601–609.
51. Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, Rademakers R, Vandenberghe R, Dermaut B, Martin J-J, van Duijn C, Peeters K, Sciot R, Santens P, De Pooter T, Mattheijssens M, Van den Broeck M, Cuijt I, Vennekens K, De Deyn PP, Kumar-Singh S, Van Broeckhoven C. 2006. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442:920–924.
52. Cunningham CL, Martinez-Cerdeno V, Noctor SC. 2013. Microglia regulate the number of neural precursor cells in the developing cerebral cortex. J Neurosci 33:4216–4233.
53. Dagher NN, Najafi AR, Kayala KMN, Elmore MRP, White TE, Medeiros R, West BL, Green KN. 2015. Colony-stimulating factor 1 receptor inhibition prevents microglial plaque association and improves cognition in 3xTg-AD mice. J Neuroinflamm 12:1–14.
54. Damani MR, Zhao L, Fontainhas AM, Amaral J, Fariss RN, Wong WT. 2011. Age-related alterations in the dynamic behavior of microglia. Aging Cell 10:263–276.
55. Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, Gan WB. 2005. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 8:752–758.
56. De Jager PL, Srivastava G, Lunnon K, Burgess J, Schalkwyk LC, Yu L, Eaton ML, Keenan BT, Ernst J, McCabe C, Tang A, Raj T, Replogle J, Brodeur W, Gabriel S, Chai HS, Younkin C, Younkin SG, Zou F, Szyf M, Epstein CB, Schneider JA, Bernstein BE, Meissner A, Ertekin-Taner N, Chibnik LB, Kellis M, Mill J, Bennett DA. 2014. Alzheimer's disease: Early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nat Neurosci 17:1156–1163.
57. DeMattos RB, Bales KR, Cummins DJ, Dodart J-C, Paul SM, Holtzman DM. 2001. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98:8850–8855.
58. DeMattos RB, Lu J, Tang Y, Racke MM, DeLong CA, Tzaferis JA, Hole JT, Forster BM, McDonnell PC, Liu F. 2012. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice. Neuron 76:908–920.
59. Dunkelberger JR, Song WC. 2010. Complement and its role in innate and adaptive immune responses. Cell Res 20:34–50.
60. Dunstan R, Bussiere T, Engber T, Weinreb P, Maier M, Grimm J, Rhodes K, Arastu M, Li M, Zhang X. 2011. The role of brain macrophages on the clearance of amyloid plaques following the treatment of Tg2576 with BIIB037. Alzheimer Dementia 7:S700.
61. Eggen BJ, Raj D, Hanisch UK, Boddeke HW. 2013. Microglial phenotype and adaptation. J Neuroimmune Pharmacol 8:807–823.
62. Eikelenboom P, Stam F. 1982. Immunoglobulins and complement factors in senile plaques. Acta Neuropathol 57:239–242.
63. El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, Luster AD. 2007. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 13:432–438.
64. Elmore MR, Najafi AR, Koike MA, Dagher NN, Spangenberg EE, Rice RA, Kitazawa M, Matusow B, Nguyen H, West BL, Green KN. 2014. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron 82:380–397.
65. Erion JR, Wosiski-Kuhn M, Dey A, Hao S, Davis CL, Pollock NK, Stranahan AM. 2014. Obesity elicits interleukin 1-mediated deficits in hippocampal synaptic plasticity. J Neurosci 34:2618–2631.
66. Erny D, Hrabe de Angelis AL, Jaitin D, Wieghofer P, Staszewski O, David E, Keren-Shaul H, Mahlakoiv T, Jakobshagen K, Buch T, Schwierzeck V, Utermohlen O, Chun E, Garrett WS, McCoy KD, Diefenbach A, Staeheli P, Stecher B, Amit I, Prinz M. 2015. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci 18:965–977.
67. Eyo UB, Peng J, Swiatkowski P, Mukherjee A, Bispo A, Wu L-J. 2014. Neuronal hyperactivity recruits microglial processes via neuronal NMDA receptors and microglial P2Y12 receptors after status epilepticus. J Neurosci 34:10528–10540.
68. Fagan AM, Holtzman DM. 2000. Astrocyte lipoproteins, effects of apoE on neuronal function, and role of apoE in amyloid-beta deposition in vivo. Microsc Res Tech 50:297–304.
69. Fenoglio C, Galimberti D, Cortini F, Kauwe JS, Cruchaga C, Venturelli E, Villa C, Serpente M, Scalabrini D, Mayo K, Piccio LM, Clerici F, Albani D, Mariani C, Forloni G, Bresolin N, Goate AM, Scarpini E. 2009. rs5848 variant influences GRN mRNA levels in brain and peripheral mononuclear cells in patients with Alzheimer's disease. J Alzheimers Dis 18:603–612.
70. Fu HJ, Liu B, Frost JL, Lemere CA. 2010. Amyloid-beta immunotherapy for Alzheimer's disease. CNS Neurol Disord Drug Targets 9:197–206.
71. Fuller JP, Stavenhagen JB, Christensen S, Kartberg F, Glennie MJ, Teeling JL. 2015. Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies. Acta Neuropathol 130:699–711.
72. Fuller JP, Stavenhagen JB, Teeling JL. 2014. New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's disease. Front Neurosci 8:235.
73. Gao X, Joselin AP, Wang L, Kar A, Ray P, Bateman A, Goate AM, Wu JY. 2010. Progranulin promotes neurite outgrowth and neuronal differentiation by regulating GSK-3beta. Protein Cell 1:552–562.
74. Gertig U, Hanisch U-K. 2014. Microglial diversity by responses and responders. Front Cell Neurosci 8:101.
75. Gotzl JK, Mori K, Damme M, Fellerer K, Tahirovic S, Kleinberger G, Janssens J, van der Zee J, Lang CM, Kremmer E, Martin JJ, Engelborghs S, Kretzschmar HA, Arzberger T, Van Broeckhoven C, Haass C, Capell A. 2014. Common pathobiochemical hallmarks of progranulin-associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis. Acta Neuropathol 127:845–860.
76. Grammas P. 2011. Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease. J Neuroinflamm 8:26.
77. Grehan S, Tse E, Taylor JM. 2001. Two distal downstream enhancers direct expression of the human apolipoprotein E gene to astrocytes in the brain. J Neurosci 21:812–822.
78. Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, Hooli B, Choi SH, Hyman BT, Tanzi RE. 2013. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 78:631–643.
79. Guerreiro R, Brás J, Hardy J. 2013a. SnapShot: Genetics of Alzheimer's disease. Cell 155:e968–e961.
80. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert JC, Amouyel P, Goate A, Rademakers R, Morgan K, Powell J, St George-Hyslop P, Singleton A, Hardy JG, Alzheimer genetic analysis. 2013b. TREM2 variants in Alzheimer's disease. N Engl J Med 368:117–127.
81. Hafezi-Moghadam A, Thomas KL, Wagner DD. 2007. ApoE deficiency leads to a progressive age-dependent blood-brain barrier leakage. Am J Physiol Cell Physiol 292:C1256–C1262.
82. Halliday MR, Rege SV, Ma Q, Zhao Z, Miller CA, Winkler EA, Zlokovic BV. 2015. Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease. J Cereb Blood Flow Metab. 36:216–227.
83. Hanisch UK, Kettenmann H. 2007. Microglia: Active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 10:1387–1394.
84. Hao S, Dey A, Yu X, Stranahan AM. 2016. Dietary obesity reversibly induces synaptic stripping by microglia and impairs hippocampal plasticity. Brain Behav Immunity 51:230–239.
85. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, Heun R, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J. 2009. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41:1088–1093.
86. Hayashi Y, Ishibashi H, Hashimoto K, Nakanishi H. 2006. Potentiation of the NMDA receptor-mediated responses through the activation of the glycine site by microglia secreting soluble factors. Glia 53:660–668.
87. Haynes SE, Hollopeter G, Yang G, Kurpius D, Dailey ME, Gan W-B, Julius D. 2006. The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat Neurosci 9:1512–1519.
88. Hickman SE, Allison EK, El Khoury J. 2008. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci 28:8354–8360.
89. Hickman SE, Kingery ND, Ohsumi TK, Borowsky ML, Wang LC, Means TK, El Khoury J. 2013. The microglial sensome revealed by direct RNA sequencing. Nat Neurosci 16:1896–1905.
90. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Beaumont H, Warden D, Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy ER, Hardy J, Mead S, Fox NC, Rossor M, Collinge J, Maier W, Jessen F, Ruther E, Schurmann B, Heun R, Kolsch H, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Gallacher J, Hull M, Rujescu D, Giegling I, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, Deyn D, Van Broeckhoven PP, Livingston C, Bass G, Gurling NJ, McQuillin H, Gwilliam A, Deloukas R, Al-Chalabi P, Shaw A, Tsolaki CE, Singleton M, Guerreiro AB, Muhleisen R, Nothen TW, Moebus MM, Jockel S, Klopp KH, Wichmann N, Pankratz HE, Sando VS, Aasly SB, Barcikowska JO, Wszolek M, Dickson ZK, Graff-Radford DW, Petersen NR, van Duijn RC, Breteler CM, Ikram MM, DeStefano MA, Fitzpatrick AL, Lopez AL, Launer O, Seshadri LJ, Berr S, Campion C, Epelbaum D, Dartigues J, Tzourio JF, C, Alperovitch A, Lathrop M, Feulner TM, Friedrich P, Riehle C, Krawczak M, Schreiber S, Mayhaus M, Nicolhaus S, Wagenpfeil S, Steinberg S, Stefansson H, Stefansson K, Snaedal J, Bjornsson S, Jonsson PV, Chouraki V, Genier-Boley B, Hiltunen M, Soininen H, Combarros O, Zelenika D, Delepine M, Bullido MJ, Pasquier F, Mateo I, Frank-Garcia A, Porcellini E, Hanon O, Coto E, Alvarez V, Bosco P, Siciliano G, Mancuso M, Panza F, Solfrizzi V, Nacmias B, Sorbi S, Bossu P, Piccardi P, Arosio B, Annoni G, Seripa D, Pilotto A, Scarpini E, Galimberti D, Brice A, Hannequin D, Licastro F, Jones L, Holmans PA, Jonsson T, Riemenschneider M, Morgan K, Younkin SG, Owen MJ, O'Donovan M, Amouyel P, Williams J. 2011. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 43:429–435.
91. Holtman IR, Raj DD, Miller JA, Schaafsma W, Yin Z, Brouwer N, Wes PD, Moller T, Orre M, Kamphuis W, Hol EM, Boddeke EW, Eggen BJ. 2015. Induction of a common microglia gene expression signature by aging and neurodegenerative conditions: A co-expression meta-analysis. Acta Neuropathol Commun 3:31.
92. Hong S, Dissing-Olesen L, Stevens B. 2016. New insights on the role of microglia in synaptic pruning in health and disease. Curr Opin Neurobiol 36:128–134.
93. Hsieh CL, Koike M, Spusta SC, Niemi EC, Yenari M, Nakamura MC, Seaman WE. 2009. A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem 109:1144–1156.
94. Hu F, Padukkavidana T, Vaegter CB, Brady OA, Zheng Y, Mackenzie IR, Feldman HH, Nykjaer A, Strittmatter SM. 2010. Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron 68:654–667.
95. Hu J, Liu C-C, Chen X-F, Zhang Y-w, Xu H, Bu G. 2015. Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement mice. Mol Neurodegen 10:1–11.
96. Hu X, Pickering E, Liu YC, Hall S, Fournier H, Katz E, Dechairo B, John S, Van Eerdewegh P, Soares H. 2011. Meta-analysis for genome-wide association study identifies multiple variants at the BIN1 locus associated with late-onset Alzheimer's disease. PLoS ONE 6:e16616.
97. Huang Y, Mucke L. 2012. Alzheimer mechanisms and therapeutic strategies. Cell 148:1204–1222.
98. Hubert P, Amigorena S. 2012. Antibody-dependent cell cytotoxicity in monoclonal antibody-mediated tumor immunotherapy. Oncoimmunology 1:103–105.
99. Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. 1989. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol 24:173–182.
100. Ittner A, Bertz J, Suh LS, Stevens CH, Götz J, Ittner LM. 2015. Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice. J Neurochem 132:135–145.
101. Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL, Cotleur AC, Butovsky O, Bekris L, Staugaitis SM, Leverenz JB, Pimplikar SW, Landreth GE, Howell GR, Ransohoff RM, Lamb BT. 2015. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J Exp Med 212:287–295.
102. Jin SC, Pastor P, Cooper B, Cervantes S, Benitez BA, Razquin C, Goate A, Cruchaga C. 2012. Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer's disease Ibero-American cohort. Alzheimer Res Ther 4:34.
103. Jönsson F, Daëron M. 2012. Mast cells & company. Front Immunol 3:16.
104. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, van Duijn CM, Thorsteinsdottir U, Kong A, Stefansson K. 2013. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 368:107–116.
105. Jun G, Naj AC, Beecham GW, Wang LS, Buros J, Gallins PJ, Buxbaum JD, Ertekin-Taner N, Fallin MD, Friedland R, Inzelberg R, Kramer P, Rogaeva E, St George-Hyslop P, Cantwell LB, Dombroski BA, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Lunetta KL, Martin ER, Montine TJ, Goate AM, Blacker D, Tsuang DW, Beekly D, Cupples LA, Hakonarson H, Kukull W, Foroud TM, Haines J, Mayeux R, Farrer LA, Pericak-Vance MA, Schellenberg GD. 2010. Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol 67:1473–1484.
106. Kaplow JM, Kusnetov G, Mastroeni D, Navia B, Kumar N, Biscaro B, Koyama A, Möller C, Lai R, Swanson C, Logovinsky V, Lannfelt L, Satlin A, Rogers J. 2013. Microglial involvement and amyloid reduction with BAN2401/mAb158, a monoclonal antibody with high selectivity for protofibrils: in vitro and ex vivo analyses. Alzheimer Dementia 9:P807–P808.
107. Karch CM, Cruchaga C, Goate AM. 2014. Alzheimer's disease genetics: From the bench to the clinic. Neuron 83:11–26.
108. Karch CM, Goate AM. 2015. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry 77:43–51.
109. Karch CM, Jeng AT, Nowotny P, Cady J, Cruchaga C, Goate AM. 2012. Expression of novel Alzheimer's disease risk genes in control and Alzheimer's disease brains. PLoS ONE 7:e50976.
110. Kelley BJ, Haidar W, Boeve BF, Baker M, Shiung M, Knopman DS, Rademakers R, Hutton M, Adamson J, Kuntz KM, Dickson DW, Parisi JE, Smith GE, Petersen RC. 2010. Alzheimer disease-like phenotype associated with the c.154delA mutation in progranulin. Arch Neurol 67:171–177.
111. Kettenmann H, Kirchhoff F, Verkhratsky A. 2013. Microglia: new roles for the synaptic stripper. Neuron 77:10–18.
112. Kim J, Basak JM, Holtzman DM. 2009. The role of apolipoprotein E in Alzheimer's disease. Neuron 63:287–303.
113. Kinder M, Greenplate AR, Strohl WR, Jordan RE, Brezski RJ. 2015. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions. mAbs 7:494–504.
114. Kitazawa M, Cheng D, Tsukamoto MR, Koike MA, Wes PD, Vasilevko V, Cribbs DH, LaFerla FM. 2011. Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer's disease model. J Immunol 187:6539–6549.
115. Kleinberger G, Yamanishi Y, Suarez-Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, Wenninger-Weinzierl A, Mazaheri F, Tahirovic S, Lleo A, Alcolea D, Fortea J, Willem M, Lammich S, Molinuevo JL, Sanchez-Valle R, Antonell A, Ramirez A, Heneka MT, Sleegers K, van der Zee J, Martin JJ, Engelborghs S, Demirtas-Tatlidede A, Zetterberg H, Van Broeckhoven C, Gurvit H, Wyss-Coray T, Hardy J, Colonna M, Haass C. 2014. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med 6:243ra286.
116. Koenigsknecht-Talboo J, Meyer-Luehmann M, Parsadanian M, Garcia-Alloza M, Finn MB, Hyman BT, Bacskai BJ, Holtzman DM. 2008. Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J Neurosci 28:14156–14164.
117. La Porte SL, Bollini SS, Lanz TA, Abdiche YN, Rusnak AS, Ho W-H, Kobayashi D, Harrabi O, Pappas D, Mina EW. 2012. Structural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J Mol Biol 421:525–536.
118. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fievet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanche H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alperovitch A, Lathrop M, Amouyel P. 2009. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41:1094–1099.
119. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thorton-Wells TA, Jones N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y, Lin CF, Gerrish A, Schmidt H, Kunkle B, Dunstan ML, Ruiz A, Bihoreau MT, Choi SH, Reitz C, Pasquier F, Cruchaga C, Craig D, Amin N, Berr C, Lopez OL, De Jager PL, Deramecourt V, Johnston JA, Evans D, Lovestone S, Letenneur L, Moron FJ, Rubinsztein DC, Eiriksdottir G, Sleegers K, Goate AM, Fievet N, Huentelman MW, Gill M, Brown K, Kamboh MI, Keller L, Barberger-Gateau P, McGuiness B, Larson EB, Green R, Myers AJ, Dufouil C, Todd S, Wallon D, Love S, Rogaeva E, Gallacher J, St George-Hyslop P, Clarimon J, Lleo A, Bayer A, Tsuang DW, Yu L, Tsolaki M, Bossu P, Spalletta G, Proitsi P, Collinge J, Sorbi S, Sanchez-Garcia F, Fox NC, Hardy J, Deniz Naranjo MC, Bosco P, Clarke R, Brayne C, Galimberti D, Mancuso M, Matthews F, Moebus S, Mecocci P, Del Zompo M, Maier W, Hampel H, Pilotto A, Bullido M, Panza F, Caffarra P, Nacmias B, Gilbert JR, Mayhaus M, Lannefelt L, Hakonarson H, Pichler S, Carrasquillo MM, Ingelsson M, Beekly D, Alvarez V, Zou F, Valladares O, Younkin SG, Coto E, Hamilton-Nelson KL, Gu W, Razquin C, Pastor P, Mateo I, Owen MJ, Faber KM, Jonsson PV, Combarros O, O'Donovan MC, Cantwell LB, Soininen H, Blacker D, Mead S, Mosley TH Jr, Bennett DA, Harris TB, Fratiglioni L, Holmes C, de Bruijn RF, Passmore P, M, TJ, Bettens K, Rotter JI, Brice A, Morgan K, Foroud TM, Kukull WA, Hannequin D, Powell JF, Nalls MA, Ritchie K, Lunetta KL, Kauwe JS, Boerwinkle E, Riemenschneider M, Boada M, Hiltuenen M, Martin ER, Schmidt R, Rujescu D, Wang LS, Dartigues JF, Mayeux R, Tzourio C, Hofman A, Nothen MM, Graff C, Psaty BM, Jones L, Haines JL, Holmans PA, Lathrop M, Pericak-Vance MA, Launer LJ, Farrer LA, van Duijn CM, Van Broeckhoven C, Moskvina V, Seshadri S, Williams J. Schellenberg GD, Amouyel P, 2013. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 45:1452–1458.
120. Lee JH, Cheng R, Barral S, Reitz C, Medrano M, Lantigua R, Jimenez-Velazquez IZ, Rogaeva E, St George-Hyslop PH, Mayeux R. 2011. Identification of novel loci for Alzheimer disease and replication of CLU, PICALM, and BIN1 in Caribbean Hispanic individuals. Arch Neurol 68:320–328.
121. Lee WC, Almeida S, Prudencio M, Caulfield TR, Zhang YJ, Tay WM, Bauer PO, Chew J, Sasaguri H, Jansen-West KR, Gendron TF, Stetler CT, Finch N, Mackenzie IR, Rademakers R, Gao FB, Petrucelli L. 2014. Targeted manipulation of the sortilin-progranulin axis rescues progranulin haploinsufficiency. Hum Mol Genet 23:1467–1478.
122. Li X, Montine KS, Keene CD, Montine TJ. 2015. Different mechanisms of apolipoprotein E isoform-dependent modulation of prostaglandin E2 production and triggering receptor expressed on myeloid cells 2 (TREM2) expression after innate immune activation of microglia. FASEB J 29:1754–1762.
123. Li Y, Liu L, Barger SW, Griffin WS. 2003. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci 23:1605–1611.
124. Liu C-C, Kanekiyo T, Xu H, Bu G. 2013. Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol 9:106–118.
125. Loke J, Khan JN, Wilson JS, Craddock C, Wheatley K. 2015. Mylotarg has potent anti-leukaemic effect: A systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia. Ann Hematol 94:361–373.
126. Lucin KM, Wyss-Coray T. 2009. Immune activation in brain aging and neurodegeneration: Too much or too little? Neuron 64:110–122.
127. Mahley RW, Huang Y. 2012. Small-molecule structure correctors target abnormal protein structure and function: Structure corrector rescue of apolipoprotein E4–associated neuropathology. J Med Chem 55:8997–9008.
128. Malik M, Simpson JF, Parikh I, Wilfred BR, Fardo DW, Nelson PT, Estus S. 2013. CD33 Alzheimer's risk-altering polymorphism, CD33 expression, and exon 2 splicing. J Neurosci 33:13320–13325.
129. Manolio TA. 2013. Bringing genome-wide association findings into clinical use. Nat Rev Genet 14:549–558.
130. Maphis N, Xu G, Kokiko-Cochran ON, Cardona AE, Rasohoff RM, Lamb BT, Bhaskar K. 2015a. Loss of tau rescues inflammation-mediated neurodegeneration. Front Neurosci 9:196.
131. Maphis N, Xu G, Kokiko-Cochran ON, Jiang S, Cardona A, Ransohoff RM, Lamb BT, Bhaskar K. 2015b. Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. Brain 138:1738–1755.
132. Marsh SE, Abud EM, Lakatos A, Karimzadeh A, Yeung ST, Davtyan H, Fote GM, Lau L, Weinger JG, Lane TE, Inlay MA, Poon WW, Blurton-Jones M. 2016. The adaptive immune system restrains Alzheimer's disease pathogenesis by modulating microglial function. Proc Natl Acad Sci USA 113:E1316–E1325.
133. Martens LH, Zhang J, Barmada SJ, Zhou P, Kamiya S, Sun B, Min SW, Gan L, Finkbeiner S, Huang EJ, Farese RV Jr. 2012. Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury. J Clin Invest 122:3955–3959.
134. Matt SM, Johnson RW. 2016. Neuro-immune dysfunction during brain aging: New insights in microglial cell regulation. Curr Opin Pharmcol 26:96–101.
135. McGeer PL, McGeer E. 2003. Is there a future for vaccination as a treatment for Alzheimer's disease? Neurobiol Aging 24:391–395.
136. McPhail GL, Clancy JP. 2013. Ivacaftor: The first therapy acting on the primary cause of cystic fibrosis. Drugs Today (Barc) 49:253–260.
137. Medina PJ, Adams VR. 2016. PD-1 pathway inhibitors: immuno-oncology agents for restoring antitumor immune responses. Pharmacotherapy 36:317–34.
138. Methia N, Andre P, Hafezi-Moghadam A, Economopoulos M, Thomas KL, Wagner DD. 2001. ApoE deficiency compromises the blood brain barrier especially after injury. Mol Med (Cambridge, Mass) 7:810–815.
139. Mhatre SD, Tsai CA, Rubin AJ, James ML, Andreasson KI. 2015. Microglial malfunction: the third rail in the development of Alzheimer's disease. Trends Neurosci 38:621–636.
140. Miller JA, Woltjer RL, Goodenbour JM, Horvath S, Geschwind DH. 2013. Genes and pathways underlying regional and cell type changes in Alzheimer's disease. Genome Med 5:48.
141. Miller KR, Streit WJ. 2007. The effects of aging, injury and disease on microglial function: A case for cellular senescence. Neuron Glia Biol 3:245–253.
142. Minami SS, Min SW, Krabbe G, Wang C, Zhou Y, Asgarov R, Li Y, Martens LH, Elia LP, Ward ME, Mucke L, Farese RV Jr, Gan L. 2014. Progranulin protects against amyloid beta deposition and toxicity in Alzheimer's disease mouse models. Nat Med 20:1157–1164.
143. Moreth J, Mavoungou C, Schindowski K. 2013. Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets? Immunity Ageing 10:18.
144. Morgan D. 2005. Mechanisms of A beta plaque clearance following passive A beta immunization. Neurodegen Dis 2:261–266.
145. Morgan D. 2011. Immunotherapy for Alzheimer's disease. J Int Med 269:54–63.
146. Moriguchi S, Mizoguchi Y, Tomimatsu Y, Hayashi Y, Kadowaki T, Kagamiishi Y, Katsube N, Yamamoto K, Inoue K, Watanabe S, Nabekura J, Nakanishi H. 2003. Potentiation of NMDA receptor-mediated synaptic responses by microglia. Mol Brain Res 119:160–169.
147. Mountain A, Adair JR. 1992. Engineering antibodies for therapy. Biotechnol Genet Eng Rev 10:1–142.
148. N'Diaye EN, Branda CS, Branda SS, Nevarez L, Colonna M, Lowell C, Hamerman JA, Seaman WE. 2009. TREM-2 (triggering receptor expressed on myeloid cells 2) is a phagocytic receptor for bacteria. J Cell Biol 184:215–223.
149. Naj A, Jun G, Buros J, Gallins P, Farrer L, Haines J, Pericak-Vance M, Schellenberg G. 2011a. Genome-wide association study of late-onset alzheimer disease identifies disease-associated variants in MS4A4/MS4A6E, CD2AP, CD33, and EPHA1. Alzheimer Dementia 7:S191.
150. Naj AC, Jun G, Beecham GW, Wang L-S, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, GraffRadford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, Cruchaga C, Kauwe JSK, Nowotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT, Green RC, Rogaeva E, GeorgeHyslop PS, Arnold SE, Barber R, Beach T, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Carlson CS, Carney RM, Carroll SL, Chui HC, Clark, DG, Corneveaux J, Cotman CW, Cummings JL, DeCarli C, DeKosky ST, Diaz-Arrastia R, Dick M, Dickson DW, Ellis WG, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Giordani B, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin L-W, Johnson N, Karlawish J, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Lah JJ, Levey AI, Lieberman AP, Lopez OL, Mack WJ, Marson DC, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Parisi JE, Perl DP, Peskind E, Petersen RC, Poon WW, Quinn JF, Rajbhandary RA, Raskind M, Reisberg B, Ringman JM, Roberson ED, Rosenberg RN, Sano M, Schneider LS, Seeley W, Shelanski ML, Slifer MA, Smith CD, Sonnen JA, Spina S, Stern RA, Tanzi, RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Vinters HV, Vonsattel JP, Weintraub S, WelshBohmer KA, Williamson J, Woltjer RL, Cantwell LB, Dombroski BA, Beekly D, Lunetta KL, Martin ER, Kamboh MI, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Montine TJ, Goate AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA, Foroud TM, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD. 2011b. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 43:436–441.
151. Natoli G, Monticelli S. 2014. Macrophage activation: Glancing into diversity. Immunity 40:175–177.
152. Neumann H, Takahashi K. 2007. Essential role of the microglial triggering receptor expressed on myeloid cells-2 (TREM2) for central nervous tissue immune homeostasis. J Neuroimmunol 184:92–99.
153. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. 2003. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: A case report. Nat Med 9:448–452.
154. Nimmerjahn A, Kirchhoff F, Helmchen F. 2005a. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308:1314–1318.
155. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. 2005b. FcgammaRIV: A novel FcR with distinct IgG subclass specificity. Immunity 23:41–51.
156. Nishitsuji K, Hosono T, Nakamura T, Bu G, Michikawa M. 2011. Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain barrier model. J Biol Chem 286:17536–17542.
157. O'Connor JJ, Coogan AN. 1999. Actions of the proinflammatory cytokine IL-1 beta on central synaptic transmission. Exp Physiol 84:601–614.
158. Okun E, Mattson MP, Arumugam TV. 2010. Involvement of Fc receptors in disorders of the central nervous system. Neuromol Med 12:164–178.
159. Olah M, Amor S, Brouwer N, Vinet J, Eggen B, Biber K, Boddeke HW. 2012. Identification of a microglia phenotype supportive of remyelination. Glia 60:306–321.
160. Olmos-Alonso A, Schetters STT, Sri S, Askew K, Mancuso R, Vargas-Caballero M, Holscher C, Perry VH, Gomez-Nicola D. 2016. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology. Brain 139:891–907.
161. Orre M, Kamphuis W, Osborn LM, Melief J, Kooijman L, Huitinga I, Klooster J, Bossers K, Hol EM. 2014. Acute isolation and transcriptome characterization of cortical astrocytes and microglia from young and aged mice. Neurobiol Aging 35:1–14.
162. Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, Klunk WE, Ashford E, Yoo K, Xu Z-X. 2012a. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 69:198–207.
163. Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, Klunk WE, Ashford E, Yoo K, Xu ZX, Loetscher H, Santarelli L. 2012b. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 69:198–207.
164. Paloneva J, Autti T, Raininko R, Partanen J, Salonen O, Puranen M, Hakola P, Haltia M. 2001. CNS manifestations of Nasu-Hakola disease: A frontal dementia with bone cysts. Neurology 56:1552–1558.
165. Paloneva J, Manninen T, Christman G, Hovanes K, Mandelin J, Adolfsson R, Bianchin M, Bird T, Miranda R, Salmaggi A, Tranebjaerg L, Konttinen Y, Peltonen L. 2002. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet 71:656–662.
166. Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, Giustetto M, Ferreira TA, Guiducci E, Dumas L, Ragozzino D, Gross CT. 2011. Synaptic pruning by microglia is necessary for normal brain development. Science 333:1456–1458.
167. Parkhurst CN, Yang G, Ninan I, Savas JN, Yates JR III, Lafaille JJ, Hempstead BL, Littman DR, Gan W-B. 2013. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell 155:1596–1609.
168. Paul J, Strickland S, Melchor JP. 2007. Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J Exp Med 204:1999–2008.
169. Pedersen JT, Sigurdsson EM. 2015. Tau immunotherapy for Alzheimer's disease. Trends Mol Med 21:394–402.
170. Peress NS, Fleit HB, Perillo E, Kuljis R, Pezzullo C. 1993. Identification of Fc gamma RI, II and III on normal human brain ramified microglia and on microglia in senile plaques in Alzheimer's disease. J Neuroimmunol 48:71–79.
171. Pitas R, Boyles J, Lee S, Hui D, Weisgraber K. 1987. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B, E (LDL) receptors in the brain. J Biol Chem 262:14352–14360.
172. Poduslo JF, Curran GL, Berg CT. 1994. Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc Natl Acad Sci USA 91:5705–5709.
173. Poliani PL, Wang Y, Fontana E, Robinette ML, Yamanishi Y, Gilfillan S, Colonna M. 2015. TREM2 sustains microglial expansion during aging and response to demyelination. J Clin Invest 125:2161–2170.
174. Prince, M, Wimo, A, Guerchet, M, Ali, G-C, Wu, Y-T, Prina, M. 2015. World Alzheimer report 2015: The global impact of dementia (Alzheimer's Disease International), Alzheimer's Disease International (ADI), London.
175. Raj DDA, Jaarsma D, Holtman IR, Olah M, Ferreira FM, Schaafsma W, Brouwer N, Meijer MM, de Waard MC, van der Pluijm I, Brandt R, Kreft KL, Laman JD, de Haan G, Biber KPH, Hoeijmakers JHJ, Eggen BJL, Boddeke HWGM. 2014. Priming of microglia in a DNA-repair deficient model of accelerated aging. Neurobiol Aging 35:2147–2160.
176. Raj T, Ryan KJ, Replogle JM, Chibnik LB, Rosenkrantz L, Tang A, Rothamel K, Stranger BE, Bennett DA, Evans DA, De Jager PL, Bradshaw EM. 2013. CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer's disease susceptibility. Hum Mol Genet 23:2729–2736.
177. Ramanan VK, Risacher SL, Nho K, Kim S, Shen L, McDonald BC, Yoder KK, Hutchins GD, West JD, Tallman EF, Gao S, Foroud TM, Farlow MR, De Jager PL, Bennett DA, Aisen PS, Petersen RC, Jack CR Jr, Toga AW, Green RC, Jagust WJ, Weiner MW, Saykin AJ. 2015. GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP. Brain 138:3076–3088.
178. Reardon S. 2015. Antibody drugs for Alzheimer's show glimmers of promise. Nature 523:509–510.
179. Replogle JM, Chan G, White CC, Raj T, Winn PA, Evans DA, Sperling RA, Chibnik LB, Bradshaw EM, Schneider JA, Bennett DA, De Jager PL. 2015. A TREM1 variant alters the accumulation of Alzheimer-related amyloid pathology. Ann Neurol 77:469–477.
180. Rosse G. 2013. HDAC inhibitors as targeted treatment of frontotemporal lobar degeneration. ACS Med Chem Lett 4:7–7.
181. Roumier A, Bechade C, Poncer JC, Smalla KH, Tomasello E, Vivier E, Gundelfinger ED, Triller A, Bessis A. 2004. Impaired synaptic function in the microglial KARAP/DAP12-deficient mouse. J Neurosci 24:11421–11428.
182. Ryu JK, Davalos D, Akassoglou K. 2009. Fibrinogen signal transduction in the nervous system. J Thromb Haemost 7:151–154.
183. Salfeld JG. 2007. Isotype selection in antibody engineering. Nat Biotechnol 25:1369–1372.
184. Salloway S, Gur T, Berzin T, Tavares R, Zipser B, Correia S, Hovanesian V, Fallon J, Kuo-Leblanc V, Glass D, Hulette C, Rosenberg C, Vitek M, Stopa E. 2002. Effect of APOE genotype on microvascular basement membrane in Alzheimer's disease. J Neurol Sci 203:183–187.
185. Salloway S, Sperling R, Gilman S, Fox N, Blennow K, Raskind M, Sabbagh M, Honig L, Doody R, Van Dyck C. 2009a. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73:2061–2070.
186. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M, Bapineuzumab 201 Clinical Trial, I. 2009b. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73:2061–2070.
187. Sandborn WJ, Yednock TA. 2003. Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am J Gastroenterol 98:2372–2382.
188. Sankaranarayanan S, Barten DM, Vana L, Devidze N, Yang L, Cadelina G, Hoque N, DeCarr L, Keenan S, Lin A, Cao Y, Snyder B, Zhang B, Nitla M, Hirschfeld G, Barrezueta N, Polson C, Wes P, Rangan VS, Cacace A, Albright CF, Meredith J Jr, Trojanowski JQ, Lee VMY, Brunden KR, Ahlijanian M. 2015. Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models. PLoS ONE 10:e0125614.
189. Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, Ransohoff RM, Greenberg ME, Barres BA, Stevens B. 2012. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 74:691–705.
190. Schafer DP, Lehrman EK, Stevens B. 2013. The “quad-partite” synapse: microglia-synapse interactions in the developing and mature CNS. Glia 61:24–36.
191. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P. 1999. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173–177.
192. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, Bis JC, Smith AV, Carassquillo MM, Lambert JC, Harold D, Schrijvers EM, Ramirez-Lorca R, Debette S, Longstreth WT Jr, Janssens AC, Pankratz VS, Dartigues JF, Hollingworth P, Aspelund T, Hernandez I, Beiser A, Kuller LH, Koudstaal PJ, Dickson DW, Tzourio C, Abraham R, Antunez C, Du Y, Rotter JI, Aulchenko YS, Harris TB, Petersen RC, Berr C, Owen MJ, Lopez-Arrieta J, Varadarajan BN, Becker JT, Rivadeneira F, Nalls MA, Graff-Radford NR, Campion D, Auerbach S, Rice K, Hofman A, Jonsson PV, Schmidt H, Lathrop M, Mosley TH, Au R, Psaty BM, Uitterlinden AG, Farrer LA, Lumley T, Ruiz A, Williams J, Amouyel P, Younkin SG, Wolf PA, Launer LJ, Lopez OL, van Duijn CM, Breteler MM. 2010. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303:1832–1840.
193. Sevigny J, Chiao P, Williams L, Chen T, Ling Y, O'Gorman J, Hock C, Nitsch RM, Sandrock A. 2015. Aducanumab (BIIB037), an anti-amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer's disease: Interim results of a randomized, double-blind, placebo-controlled, phase 1b study. Alzheimer Dementia 11:277.
194. Shen Y, Yang L, Li R. 2013. What does complement do in Alzheimer's disease? Old molecules with new insights. Transl Neurodegen 2:21.
195. Shi Q, Colodner KJ, Matousek SB, Merry K, Hong S, Kenison JE, Frost JL, Le KX, Li S, Dodart J-C, Caldarone BJ, Stevens B, Lemere CA. 2015. Complement C3-deficient mice fail to display age-related hippocampal decline. J Neurosci 35:13029–13042.
196. Siberil S, Dutertre CA, Fridman WH, Teillaud JL. 2007. FcgammaR: The key to optimize therapeutic antibodies? Crit Rev Oncol/Hematol 62:26–33.
197. Sieber MW, Jaenisch N, Brehm M, Guenther M, Linnartz-Gerlach B, Neumann H, Witte OW, Frahm C. 2013. Attenuated inflammatory response in triggering receptor expressed on myeloid cells 2 (TREM2) knock-out mice following stroke. PLoS ONE 8:e52982.
198. Sierra A, Tremblay M-E, Wake H. 2015. Never-resting microglia: Physiological roles in the healthy brain and pathological implications Front Cell Neurosci 8:240.
199. Sipe GO, Lowery RL, Tremblay ME, Kelly EA, Lamantia CE, Majewska AK. 2016. Microglial P2Y12 is necessary for synaptic plasticity in mouse visual cortex. Nat Commun 7:10905.
200. Slattery C, Beck J, Harper L, Adamson G, Abdi Z, Uphill J, Campbell T, Druyeh R, Mahoney C, Rohrer J, Kenny J, Lowe J, Leung K, Barnes J, Clegg S, Blair M, Nicholas J, Guerreiro R, Rowe J, Ponto C, Zerr I, Kretzschmar H, Gambetti P, Crutch S, Warren J, Rossor M, Fox N, Collinge J, Schott J, Mead S. 2014. TREM2 variants increase risk of typical early-onset Alzheimer's disease but not of prion or frontotemporal dementia. J Neurol Neurosurg Psychiatry 85:e3.
201. Smith KR, Damiano J, Franceschetti S, Carpenter S, Canafoglia L, Morbin M, Rossi G, Pareyson D, Mole SE, Staropoli JF, Sims KB, Lewis J, Lin WL, Dickson DW, Dahl HH, Bahlo M, Berkovic SF. 2012. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am J Hum Genet 90:1102–1107.
202. Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ. 2011. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimer Dementia 7:367–385.
203. Steinmetz CC, Turrigiano GG. 2010. Tumor necrosis factor-α signaling maintains the ability of cortical synapses to express synaptic scaling. J Neurosci 30:14685–14690.
204. Stellwagen D, Malenka RC. 2006. Synaptic scaling mediated by glial TNF-[alpha]. Nature 440:1054–1059.
205. Stelzmann RA, Norman Schnitzlein H, Reed Murtagh F. 1995. An English translation of Alzheimer's 1907 paper, “über eine eigenartige erkankung der hirnrinde”. Clin Anat 8:429–431.
206. Streit WJ, Graeber MB, Kreutzberg GW. 1988. Functional plasticity of microglia: A review. Glia 1:301–307.
207. Takahashi K, Rochford CD, Neumann H. 2005. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med 201:647–657.
208. Tanaka Y, Chambers JK, Matsuwaki T, Yamanouchi K, Nishihara M. 2014. Possible involvement of lysosomal dysfunction in pathological changes of the brain in aged progranulin-deficient mice. Acta Neuropathol Commun 2:78.
209. Tanzi RE. 2015. TREM2 and risk of alzheimer's disease–friend or foe? N Engl J Med 372:2564–2565.
210. Tapia L, Milnerwood A, Guo A, Mills F, Yoshida E, Vasuta C, Mackenzie IR, Raymond L, Cynader M, Jia W, Bamji SX. 2011. Progranulin deficiency decreases gross neural connectivity but enhances transmission at individual synapses. J Neurosci 31:11126–11132.
211. Thambisetty M, Beason-Held L, An Y, Kraut MA, Resnick SM. 2010. APOE epsilon4 genotype and longitudinal changes in cerebral blood flow in normal aging. Arch Neurol 67:93–98.
212. Tremblay ME, Lowery RL, Majewska AK. 2010. Microglial interactions with synapses are modulated by visual experience. PLoS Biol 8:e1000527.
213. Tremblay ME, Stevens B, Sierra A, Wake H, Bessis A, Nimmerjahn A. 2011. The role of microglia in the healthy brain. J Neurosci 31:16064–16069.
214. Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, Stewart FR, Piccio L, Colonna M, Holtzman DM. 2014. Altered microglial response to Abeta plaques in APPPS1-21 mice heterozygous for TREM2. Mol Neurodegener 9:20.
215. Van Damme P, Van Hoecke A, Lambrechts D, Vanacker P, Bogaert E, van Swieten J, Carmeliet P, Van Den Bosch L, Robberecht W. 2008. Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol 181:37–41.
216. Verghese PB, Castellano JM, Holtzman DM. 2011. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol 10:241–252.
217. Vidarsson G, Dekkers G, Rispens T. 2014. IgG subclasses and allotypes: from structure to effector functions. Front Immunol 5:520.
218. Villegas-Llerena C, Phillips A, Reitboeck PG, Hardy J, Pocock JM. 2016. Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease. Curr Opin Neurobiol 36:74–81.
219. Viswanathan J, Makinen P, Helisalmi S, Haapasalo A, Soininen H, Hiltunen M. 2009. An association study between granulin gene polymorphisms and Alzheimer's disease in Finnish population. Am J Med Genet B 150:747–750.
220. Vitek MP, Brown CM, Colton CA. 2009. APOE genotype-specific differences in the innate immune response. Neurobiol Aging 30:1350–1360.
221. Wake H, Moorhouse AJ, Jinno S, Kohsaka S, Nabekura J. 2009. Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J Neurosci 29:3974–3980.
222. Walker DG, Whetzel AM, Serrano G, Sue LI, Beach TG, Lue LF. 2015. Association of CD33 polymorphism rs3865444 with Alzheimer's disease pathology and CD33 expression in human cerebral cortex. Neurobiol Aging 36:571–582.
223. Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, Holtzman DM, Cirrito JR, Colonna M. 2015. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 160:1061–1071.
224. Wes PD, Easton A, Corradi J, Barten DM, Devidze N, DeCarr LB, Truong A, He A, Barrezueta NX, Polson C, Bourin C, Flynn ME, Keenan S, Lidge R, Meredith J, Natale J, Sankaranarayanan S, Cadelina GW, Albright CF, Cacace AM. 2014. Tau overexpression impacts a neuroinflammation gene expression network perturbed in Alzheimer's disease. PLoS ONE 9:e106050.
225. Wes PD, Holtman IR, Boddeke EWGM, Möller T, Eggen BJL. 2016. Next generation transcriptomics and genomics elucidate biological complexity of microglia in health and disease. Glia 64:197–213.
226. Wiesel TN, Hubel DH. 1963. Single-cell responses in striate cortex of kittens deprived of vision in one eye. J Neurophysiol 426:1003-1017.
227. Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, Gordon MN, Morgan D. 2003. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci 23:3745–3751.
228. Winiarska M, Glodkowska-Mrowka E, Bil J, Golab J. 2011. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci 16:277–306.
229. Wisniewski, HM, Terry, RD (1973). Reexamination of the pathogenesis of the senile plaque. In: Zimmermann HM, editor. Progress in neuropathology. New York: Grune and Stratton. pp 1–26.
230. Wisniewski T, Goni F. 2015. Immunotherapeutic approaches for Alzheimer's disease. Neuron 85:1162–1176.
231. Wu Y, Dissing-Olesen L, MacVicar BA, Stevens B. Microglia: Dynamic mediators of synapse development and plasticity. Trends Immunol 36:605–613.
232. Wu Y, Dissing-Olesen L, MacVicar BA, Stevens B. 2015. Microglia: dynamic mediators of synapse development and plasticity. Trends Immunol 36:605–613.
233. Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, De Nardo D, Gohel TD, Emde M, Schmidleithner L, Ganesan H, Nino-Castro A, Mallmann MR, Labzin L, Theis H, Kraut M, Beyer M, Latz E, Freeman Tom C, Ulas T Schultze JL. 2014. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 40:274–288.
234. Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM. 2013. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80:402–414.
235. Yin F, Banerjee R, Thomas B, Zhou P, Qian L, Jia T, Ma X, Ma Y, Iadecola C, Beal MF, Nathan C, Ding A. 2010. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med 207:117–128.
236. Yu YJ, Watts RJ. 2013. Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics 10:459–472.
237. Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, Atwal J, Elliott JM, Prabhu S, Watts RJ, Dennis MS. 2011. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 3:84ra44–84ra44.
238. Yu Zuchero YJ, Chen X, Bien-Ly N, Bumbaca D, Tong RK, Gao X, Zhang S, Hoyte K, Luk W, Huntley MA, Phu L, Tan C, Kallop D, Weimer RM, Lu Y, Kirkpatrick DS, Ernst JA, Chih B, Dennis MS, Watts RJ. 2016. Discovery of novel blood-brain barrier targets to enhance brain uptake of therapeutic antibodies. Neuron 89:70–82.
239. Zago W, Buttini M, Comery TA, Nishioka C, Gardai SJ, Seubert P, Games D, Bard F, Schenk D, Kinney GG. 2012. Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific. J Neurosci 32:2696–2702.
240. Zago W, Schroeter S, Guido T, Khan K, Seubert P, Yednock T, Schenk D, Gregg KM, Games D, Bard F, Kinney GG. 2013. Vascular alterations in PDAPP mice after anti-Abeta immunotherapy: Implications for amyloid-related imaging abnormalities. Alzheimer Dementia 9:S105–S115.
241. Zhan Y, Paolicelli RC, Sforazzini F, Weinhard L, Bolasco G, Pagani F, Vyssotski AL, Bifone A, Gozzi A, Ragozzino D, Gross CT. 2014. Deficient neuron-microglia signaling results in impaired functional brain connectivity and social behavior. Nat Neurosci 17:400–406.
242. Zhang B, Gaiteri C, Bodea LG, Wang Z, McElwee J, Podtelezhnikov AA, Zhang C, Xie T, Tran L, Dobrin R, Fluder E, Clurman B, Melquist S, Narayanan M, Suver C, Shah H, Mahajan M, Gillis T, Mysore J, MacDonald ME, Lamb JR, Bennett DA, Molony C, Stone DJ, Gudnason V, Myers AJ, Schadt EE, Neumann H, Zhu J, Emilsson V. 2013. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell 153:707–720.